Search

Your search keyword '"J. Crand"' showing total 4 results
Start Over Author "J. Crand"
4 results on '"J. Crand"'

1. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study

Author

J Crand, J C Rambaud, P Marteau, and M Foucault

Subjects
Adult, Male, medicine.medical_specialty, Randomization, Analgesic, Suppository, Placebo, Inflammatory bowel disease, Gastroenterology, Drug Administration Schedule, chemistry.chemical_compound, Mesalazine, Double-Blind Method, Recurrence, Internal medicine, medicine, Humans, Antipyretic, Mesalamine, Proctitis, business.industry, Suppositories, Anti-Inflammatory Agents, Non-Steroidal, Inflammatory Bowel Disease, medicine.disease, Surgery, chemistry, Delayed-Action Preparations, Colitis, Ulcerative, Female, business, medicine.drug
Abstract

Background—Daily administration of rectal formulations of mesalazine is effective in preventing relapse of ulcerative proctitis. Maintenance of remission with lower doses would be an advantage.Aim—The efficacy of mesalazine suppositories (Pentasa) 1 g three times a week v placebo to maintain remission in patients with cryptogenetic proctitis was studied.Methods—Ninety five patients with cryptogenetic proctitis were randomised within two weeks of remission to receive for one year or until relapse three suppositories per week of either Pentasa (n=48) or placebo (n=47). In the case of a relapse, the patients received one suppository/day.Results—It was found that 25 of 48 subjectsv 18 of 47 remained in remission in the mesalazine and placebo groups respectively. The relapse rate was lower in the mesalazine group for the following time intervals: 0–90 days (19%v 38%, p=0.035), 0–180 days (29% v 54%, p=0.017), 0–270 days (38% v 60%, p=0.031), and 0–365 days (48% v 62%, p=0.18). Treatment of relapse with one suppository/day induced remission in 11 of 18 and 2 of 26 patients in the mesalazine and placebo groups respectively (p=0.001). Overall, 61%v 28% patients remained in the protocol and were in remission at one year (p=0.001). Tolerance was good.Conclusion—Mesalazine suppositories 1 g three times a week are effective for preventing relapses of cryptogenetic proctitis. Increasing the dose to 1 g/day is effective in a high proportion of subjects who relapsed.

Published
1998

2. Prevention of recurrence by mesalamine (Pentasa) in pediatric Crohn's disease A multicentric double blind trial

Author

C. Maurage, Alain Lachaux, Anne Munck, Thierry Lamireau, J.Y. Mary, A. Dabadi, Dominique Charles Belli, Jean Pierre Cezard, A. Morali, M. Meyer, Jean-Philippe Girardet, B. Descos, Dominique Turck, Jacques Schmitz, C. Lenaerts, Jacques Sarles, Olivier Mouterde, J.-P. Chouraqui, J. P. Olives, and J. Crand

Subjects
Double blind, Pediatrics, medicine.medical_specialty, Hepatology, Pediatric Crohn's disease, business.industry, Gastroenterology, medicine, business
Published
2003

3. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.

Author

P, Marteau, J, Crand, M, Foucault, and C, Rambaud J

Abstract

BACKGROUND: Daily administration of rectal formulations of mesalazine is effective in preventing relapse of ulcerative proctitis. Maintenance of remission with lower doses would be an advantage. AIM: The efficacy of mesalazine suppositories (Pentasa) 1 g three times a week v placebo to maintain remission in patients with cryptogenetic proctitis was studied. METHODS: Ninety five patients with cryptogenetic proctitis were randomised within two weeks of remission to receive for one year or until relapse three suppositories per week of either Pentasa (n = 48) or placebo (n = 47). In the case of a relapse, the patients received one suppository/day. RESULTS: It was found that 25 of 48 subjects v 18 of 47 remained in remission in the mesalazine and placebo groups respectively. The relapse rate was lower in the mesalazine group for the following time intervals: 0-90 days (19% v 38%, p = 0.035), 0-180 days (29% v 54%, p = 0.017), 0-270 days (38% v 60%, p = 0.031), and 0-365 days (48% v 62%, p = 0.18). Treatment of relapse with one suppository/day induced remission in 11 of 18 and 2 of 26 patients in the mesalazine and placebo groups respectively (p = 0.001). Overall, 61% v 28% patients remained in the protocol and were in remission at one year (p = 0.001). Tolerance was good. CONCLUSION: Mesalazine suppositories 1 g three times a week are effective for preventing relapses of cryptogenetic proctitis. Increasing the dose to 1 g/day is effective in a high proportion of subjects who relapsed.

Published
1998

4. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.

Author

Marteau P, Crand J, Foucault M, and Rambaud JC

Subjects
Adult, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Delayed-Action Preparations, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Mesalamine therapeutic use, Recurrence, Suppositories, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Colitis, Ulcerative prevention & control, Mesalamine administration & dosage
Abstract

Background: Daily administration of rectal formulations of mesalazine is effective in preventing relapse of ulcerative proctitis. Maintenance of remission with lower doses would be an advantage., Aim: The efficacy of mesalazine suppositories (Pentasa) 1 g three times a week v placebo to maintain remission in patients with cryptogenetic proctitis was studied., Methods: Ninety five patients with cryptogenetic proctitis were randomised within two weeks of remission to receive for one year or until relapse three suppositories per week of either Pentasa (n = 48) or placebo (n = 47). In the case of a relapse, the patients received one suppository/day., Results: It was found that 25 of 48 subjects v 18 of 47 remained in remission in the mesalazine and placebo groups respectively. The relapse rate was lower in the mesalazine group for the following time intervals: 0-90 days (19% v 38%, p = 0.035), 0-180 days (29% v 54%, p = 0.017), 0-270 days (38% v 60%, p = 0.031), and 0-365 days (48% v 62%, p = 0.18). Treatment of relapse with one suppository/day induced remission in 11 of 18 and 2 of 26 patients in the mesalazine and placebo groups respectively (p = 0.001). Overall, 61% v 28% patients remained in the protocol and were in remission at one year (p = 0.001). Tolerance was good., Conclusion: Mesalazine suppositories 1 g three times a week are effective for preventing relapses of cryptogenetic proctitis. Increasing the dose to 1 g/day is effective in a high proportion of subjects who relapsed.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results